Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis
NCT ID: NCT02856607
Last Updated: 2016-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2014-02-28
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Only few investigations consider the prognostic and the therapeutic medical care according to the clinical care pathway. In fact, 3 situations are observed: (i) patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery, (ii) patients secondary addressed to a referent center with cardiac surgery, (iii) patients for which the totality medical care are performed in non-referent health center. In addition, epidemiologic studies concern only a part of IE, not including most of the time the patients hospitalized in non-referent center.
The aim of the study was to determine the prognosis of threated patients according to the clinical care pathway. Secondary objectives was (i) to evaluate the application of European recommendations concerning trans-oesophageal echocardiogram (TOE), antibiotic treatment and surgical practice, (ii) to compare the epidemiologic profile according to the type of center.
For this, 300 patients addressed in the 22 French participating centers for a possible or certain IE according to Duke Criteria were prospectively included during 3 years.
Patient data (clinical, demographical, biological, microbiological, echocardiographic and evolutive data) were collected at the admission, during hospitalization, at discharge and one-year follow up.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Prognosis of Infectious Endocarditis (EPEI)
NCT03211975
Inflammation and Infective Endocarditis
NCT06871215
Early Valve Surgery Versus Conventional Treatment in Infective Endocarditis Patients With High Risk of Embolism
NCT03718052
Early Surgery Versus Conventional Treatment in Infective Endocarditis
NCT00750373
Suppressive Antibiotic Therapy for Endocarditis
NCT06107309
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
determine the prognosis of threated patients according to the clinical care pathway.
Group II
patients secondary addressed to a referent center with cardiac surgery
determine the prognosis of threated patients according to the clinical care pathway.
Group III
patients for which the totality medical care are performed in non-referent health center
determine the prognosis of threated patients according to the clinical care pathway.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
determine the prognosis of threated patients according to the clinical care pathway.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Urielle DESALBRES
Role: STUDY_DIRECTOR
Assistance Publique Hôpitaux de Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Hôpoitaux de Marseille Hôpital de la Timone
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC12_3675
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.